CurrentCignaPolicy N/A

Lupus - Benlysta Subcutaneous Drug Quantity Management Policy

Defines quantity limits and exception criteria for Benlysta subcutaneous injections for Cigna-administered benefit plans, including point-of-service deny/override rules and durations of approvals.

Policy Summary

PayerCigna

PolicyLupus - Benlysta Subcutaneous Drug Quantity Management Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateSep 6, 2024

Key ActionRequest a one-time 8 mL override when initiating treatment for lupus nephritis if there are no Benlysta claims in the past 130 days.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4 mLRetail max / 28 days

12 mLHome delivery max / 84 days

8 mLOne-time override

30 daysOverride duration

Coverage Criteria for Benlysta (belimumab) SC

One-time induction / lupus nephritis exception

Policy Summary

PayerCigna

PolicyLupus - Benlysta Subcutaneous Drug Quantity Management Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateSep 6, 2024

Key ActionRequest a one-time 8 mL override when initiating treatment for lupus nephritis if there are no Benlysta claims in the past 130 days.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

One-time induction or lupus nephritis exception: Approve a one-time override for 8 mL (eight prefilled syringes or autoinjectors) at retail or home delivery when the patient is initiating treatment for lupus nephritis or requires additional induction dosing, as verified by the absence of claims for Benlysta in the past 130 days.absence of claims for Benlysta in past 130 days

One-time approvals are provided for 30 days in duration.

Product and Coding

Covered NDC / ProductNDCCovered

NDC (product description)

Benlysta (belimumab subcutaneous injection) 200 mg/mL prefilled syringe

Lookback for prior Benlysta claims

Lookback period for prior Benlysta claimsNo claims for Benlysta in the past 130 days

PurposeRequired to verify eligibility for the one-time 8 mL override for induction or lupus nephritis

Applies toPatients initiating treatment for lupus nephritis or requiring additional induction dosing

Documentation expectationAbsence of prior Benlysta claims within 130 days must be documented or verifiable in claims history

Related approval durationOne-time approvals are provided for 30 days in duration per policy notes

Provider Actions and Billing Rules

Documentation Required

Provider documentation expectations

Providers must submit appropriate diagnosis and procedure drug codes and supporting clinical documentation consistent with the member's benefit plan. Coverage determinations require review of the applicable benefit plan, relevant laws/regulations, clinical records demonstrating indication and previous therapy, and any required prior authorization forms. When billing, use the most appropriate codes as of the date of service; claims lacking covered codes will be denied. Medical directors may exercise clinical judgment for individual determinations.

Submit: relevant ICD-10 diagnosis supporting lupus nephritis or systemic lupus erythematosus.
Include: documentation of prior therapies, dates of prior Benlysta doses (if any), and clinical rationale for induction or continuation dosing.
Attach any required prior authorization forms per plan.

Step Therapy

Step therapy / sequencing

Benlysta SC is not recommended in combination with other biologic agents; IV Benlysta is not targeted by this policy. Initiation, induction, and sequence of therapy should follow clinical guidelines and the patient’s prior treatment history. If the patient has not received Benlysta in the prior 130 days and requires induction dosing (including for lupus nephritis), a one-time override for increased quantity may be appropriate per the criteria.

IV Benlysta is not addressed by this policy.
Do not combine Benlysta with other biologics.
If no Benlysta claims in past 130 days, induction dosing may be approved (see quantity-exception criteria).

Prior Authorization

Quantity limits and exception prior authorization

Retail and home-delivery quantity limits apply at the point of sale; if the Drug Quantity Management rule is not met at point of service, coverage will be determined by the policy criteria and prior authorization may be required. One-time approvals for induction are provided for 30 days.

Retail limit: 4 mL (4 prefilled syringes) per 28 days.
Home delivery limit: 12 mL (12 prefilled syringes) per 84 days.
If point-of-service rule not met, submit prior authorization with supporting documentation to avoid denial.

Denial Risk

Point-of-service quantity rule and denial risk

Point-of-service Drug Quantity Management rules may lead to claim denial if not met. To reduce denial risk, verify quantity limits at dispensing and submit documentation supporting any exception (e.g., induction dosing proof of no Benlysta claim in prior 130 days). 'One-time' approvals are 30 days; approvals per criteria will be issued for the duration specified in the policy.

Failure to meet the point-of-service quantity rule may result in denial; submit a completed prior authorization to have the request reviewed under the policy criteria.
For induction exceptions, include evidence of no Benlysta use in past 130 days.
One-time override quantity for induction: 8 mL (8 prefilled syringes) at retail or home delivery.

Definitions

Benlysta SC (product definition)

Drug and formulationBelimumab subcutaneous injection (Benlysta SC), 200 mg/mL prefilled syringe or auto-injector

Indicated populationsSystemic lupus erythematosus and lupus nephritis in patients ≥5 years of age receiving standard therapy

LimitationsNot studied or recommended for severe, active CNS lupus or in combination with other biologics; IV formulation is outside the scope of this policy

Related quantity policySubject to Drug Quantity Management limits; one-time 8 mL override allowed for induction/lupus nephritis when lookback requirement met

Background

Benlysta (belimumab) subcutaneous is supplied as a 200 mg/mL prefilled syringe or auto‑injector and is included in this Drug Quantity Management policy. The policy establishes specific quantity limits: retail maximum 4 mL per 28 days (4 prefilled syringes) and home delivery maximum 12 mL per 84 days (12 prefilled syringes). Exceptions to these limits are only permitted when the policy’s defined clinical criteria are met.